Developer docs
API playgroundTry for free, no card

Search company profiles

Morphoceuticals

Full company profile

uuid0000ln1

Namestring
Morphoceuticals
Legal namestring
Morphoceuticals, Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Morphoceuticals is a pre-revenue biotechnology company founded in 2020 that is developing AI-guided electroceutical therapeutics for tissue repair and organ regeneration. The company is building what it describes as the first atlas of the bioelectrome—a comprehensive map of the body's non-neural electrical communication networks that govern multi-cellular coordination, tissue integrity, and regenerative signaling. Its platform combines multi-omics analysis, bioelectric profiling, and AI to identify and manipulate bioelectric patterns, delivered through proprietary combinations of ion channel and gap junction modulators and a wearable bioreactor ("biodome") device. The company's most notable proof-of-concept was achieved in January 2022, when its scientific co-founders Michael Levin and David Kaplan demonstrated functional limb regeneration in adult African clawed frogs—a species that does not naturally regenerate complex limbs—with results published in Science Advances.

The company targets conditions inadequately served by existing modalities, including traumatic injuries, degenerative diseases, and organ failure. The U.S. limb-loss population alone represents an addressable market of approximately 185,000 amputations per year and a projected 3.6 million people living with limb loss by 2050. Morphoceuticals is a privately held Delaware corporation headquartered in Medford, Massachusetts, with 1-10 employees and no commercialized products. Its anticipated revenue model is licensing and royalties from pharmaceutical partners, but the company is currently funded through venture capital, having raised over $15 million in cumulative seed financings led by Juvenescence and Prime Movers Lab. The leadership team includes CEO Jim Jenson (former CEO of Dicerna Pharmaceuticals, acquired by Novo Nordisk for $3.3 billion) and Chairman Roger Pomerantz (former President/CEO of Seres Therapeutics; led 14 FDA-approved therapies at J&J and Merck).

The go-to-market motion is enterprise-oriented: Morphoceuticals is positioned as a platform company targeting eventual licensing or acquisition by large pharmaceutical companies. Distribution channels do not yet exist for commercial products; future commercialization would rely on traditional pharmaceutical distribution to healthcare providers and institutions. Marketing activity is currently limited to earned media coverage, scientific publications and presentations (TED, Science Advances, Cell, Nature Communications), and a corporate website — appropriate for a pre-revenue research-stage company building scientific credibility among investors, partners, and the academic community.

Short descriptiontext

Morphoceuticals is a pre-revenue biotechnology company developing AI-guided electroceutical therapeutics for tissue repair and organ regeneration, leveraging the bioelectrome — the body's electrical communication networks — through proprietary ion channel modulators and wearable bioreactor devices.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMedford, United States
HQ citystring
Medford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medicine platform, electroceutical therapeutics, bioelectric drug discovery, tissue regeneration biotech, ion channel modulators
Industry2 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Biological Products, (No Disgnostic Substances)2836
Product category
Regenerative Medicine Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Electroceutical Therapeutics
TypeLicensing Royalties
Description

Pre-revenue biotech company developing AI-guided electroceuticals for tissue repair and organ regeneration. Revenue generation model not yet established as company is in R&D stage.

morphoceuticals.com
2Platform Technology Licensing
TypeLicensing Royalties
Description

The company may pursue licensing agreements with large pharmaceutical companies for its bioelectrome platform technology and therapeutic candidates.

morphoceuticals.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Morphoceuticals is a TechBio company building the first atlas of the bioelectrome—the set of electrical communication networks within the body that coordinate tissue repair and organ regeneration. Using multi-omics analysis, bioelectric profiling, and proprietary AI techniques, the company discovers and develops ion channel and gap junction modulators (electroceuticals) intended to induce limb regeneration, repair tissues, regenerate organs, and treat channelopathies. The platform is delivered alongside wearable bioreactor devices (biodomes) that establish localized controlled environments for electroceutical delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Functional limb regeneration achieved in adult African clawed frogs (species that does not naturally regenerate complex limbs)
+2 more records
Product overview1 text field

Morphoceuticals is a TechBio company offering a platform technology centered on the first-ever atlas of the bioelectrome. The core platform combines multi-omics analysis, bioelectric profiling, and AI to map and manipulate the body's electrical communication networks. The technology is delivered through AI-guided electroceuticals (ion channel and gap junction modulators) and wearable bioreactor devices (biodomes) that enable targeted bioelectric signaling for tissue repair and organ regeneration. The company is pursuing applications in limb regeneration, wound healing, organ repair, and treatment of degenerative diseases and traumatic injuries.

Product and service3 records
1Bioelectrome Atlas Platform
CategoryDrug Discovery Platform
Description

First-ever atlas of the bioelectrome—a comprehensive map of electrical communication networks within the body that bind multi-cellular collectives together, built using multi-omics, bioelectric profiling, and proprietary AI techniques. Used as a discovery engine for identifying regenerative therapeutic targets.

2AI-Guided Electroceuticals
CategoryRegenerative Therapeutics
Description

Proprietary combinations of ion channel and gap junction modulators guided by AI to induce tissue regeneration, improve amputation stump health, promote organ regeneration, and treat channelopathies. Aimed at patients with traumatic injuries, degenerative diseases, and organ failure.

3Wearable Bioreactor (Biodome)
CategoryMedical Device
Description

Wearable device (biodome) that establishes a temporary hydrated and controlled environment at a stump or wound site, enabling localized delivery of electroceuticals to trigger regenerative bioelectric signaling. Used in combination with Morphoceuticals' ion channel and gap junction modulators.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-07-22
Description

LyGenesis CEO Michael Hufford serves on Morphoceuticals' Board of Directors, creating a strategic connection between the two regenerative medicine companies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Morphoceuticals was co-founded by Tufts University researchers Michael Levin and David Kaplan. The company leverages groundbreaking research from Tufts including limb regeneration demonstrated in African clawed frogs. The Allen Discovery Center at Tufts is led by Dr. Levin.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Public bioelectronic medicine company with FDA-cleared vagus nerve stimulation devices for multiple neurological conditions. Comparable through its electroceutical approach and neuromodulation platform, though applied to non-regenerative indications.

TypeDirect peer
Description

Clinical-stage cell therapy company developing in vivo organ regeneration using lymph nodes as bioreactors. Most directly comparable to Morphoceuticals through its regenerative medicine ambition, board-level connection (LyGenesis CEO Hufford serves on Morphoceuticals' board), and shared focus on organ regrowth without traditional transplantation.

TypeDirect peer
Description

Public regenerative medicine company bioengineering human tissues and vessels for implantation. Comparable through its tissue engineering platform targeting regenerative applications and pursuit of FDA approval pathways for novel regenerative products.

TypeDirect peer
Description

Clinical-stage bioelectronic medicine company developing vagus nerve stimulation for inflammatory and autoimmune diseases. Closely comparable to Morphoceuticals through its bioelectric therapeutic modality and proprietary neuro-immune mechanism, though targeting different indications.

TypeBroad incumbent
Description

Commercial-stage neuromodulation/electroceutical company with closed-loop spinal cord stimulation platform. Comparable through its use of electrical signaling to treat disease, though focused on pain management rather than regeneration.

6InVivo Therapeutics
TypeEmerging player
Description

Clinical-stage company developing neural regeneration therapies for spinal cord injury and other CNS conditions. Comparable through its regenerative medicine focus and use of novel biomaterial-based approaches for nerve repair.

TypeBroad incumbent
Description

Clinical-stage gene editing company developing human-compatible organs for xenotransplantation. Comparable through its novel approach to addressing organ failure and regenerative medicine ambitions, though via a different mechanism (xenotransplantation vs. bioelectric signaling).

TypeBroad incumbent
Description

Public clinical-stage cell therapy company developing allogeneic cell transplants for neurodegenerative, oncologic, and regenerative indications. Comparable through its regenerative medicine platform and pursuit of novel tissue-restoration therapies.

TypeBroad incumbent
Description

Public regenerative medicine company commercializing advanced wound care and surgical biologics products. Comparable through its regenerative medicine focus and commercial-stage presence, though in adjacent tissue repair applications rather than whole-organ regeneration.

TypeBroad incumbent
Description

Public regenerative medicine company marketing placental tissue allografts for wound care and surgical recovery. Comparable through its regenerative medicine positioning and focus on tissue repair, though in established wound healing markets rather than bioelectric approaches.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Morphoceuticals

Regenerative Medicine Therapeuticsmorphoceuticals.com

Morphoceuticals is a pre-revenue biotechnology company developing AI-guided electroceutical therapeutics for tissue repair and organ regeneration, leveraging the bioelectrome — the body's electrical communication networks — through proprietary ion channel modulators and wearable bioreactor devices.

What Morphoceuticals does

Morphoceuticals is a pre-revenue biotechnology company founded in 2020 that is developing AI-guided electroceutical therapeutics for tissue repair and organ regeneration. The company is building what it describes as the first atlas of the bioelectrome—a comprehensive map of the body's non-neural electrical communication networks that govern multi-cellular coordination, tissue integrity, and regenerative signaling. Its platform combines multi-omics analysis, bioelectric profiling, and AI to identify and manipulate bioelectric patterns, delivered through proprietary combinations of ion channel and gap junction modulators and a wearable bioreactor ("biodome") device. The company's most notable proof-of-concept was achieved in January 2022, when its scientific co-founders Michael Levin and David Kaplan demonstrated functional limb regeneration in adult African clawed frogs—a species that does not naturally regenerate complex limbs—with results published in Science Advances.

The company targets conditions inadequately served by existing modalities, including traumatic injuries, degenerative diseases, and organ failure. The U.S. limb-loss population alone represents an addressable market of approximately 185,000 amputations per year and a projected 3.6 million people living with limb loss by 2050. Morphoceuticals is a privately held Delaware corporation headquartered in Medford, Massachusetts, with 1-10 employees and no commercialized products. Its anticipated revenue model is licensing and royalties from pharmaceutical partners, but the company is currently funded through venture capital, having raised over $15 million in cumulative seed financings led by Juvenescence and Prime Movers Lab. The leadership team includes CEO Jim Jenson (former CEO of Dicerna Pharmaceuticals, acquired by Novo Nordisk for $3.3 billion) and Chairman Roger Pomerantz (former President/CEO of Seres Therapeutics; led 14 FDA-approved therapies at J&J and Merck).

The go-to-market motion is enterprise-oriented: Morphoceuticals is positioned as a platform company targeting eventual licensing or acquisition by large pharmaceutical companies. Distribution channels do not yet exist for commercial products; future commercialization would rely on traditional pharmaceutical distribution to healthcare providers and institutions. Marketing activity is currently limited to earned media coverage, scientific publications and presentations (TED, Science Advances, Cell, Nature Communications), and a corporate website — appropriate for a pre-revenue research-stage company building scientific credibility among investors, partners, and the academic community.

Morphoceuticals firmographics

Firmographics
Name
Morphoceuticals
Legal name
Morphoceuticals, Inc.
Website
https://morphoceuticals.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Morphoceuticals is a pre-revenue biotechnology company developing AI-guided electroceutical therapeutics for tissue repair and organ regeneration, leveraging the bioelectrome — the body's electrical communication networks — through proprietary ion channel modulators and wearable bioreactor devices.
Ownership category
akta.pro rank

Morphoceuticals industry classification

Industry
Product category
Regenerative Medicine Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Regenerative medicine platform
  • Electroceutical therapeutics
  • Bioelectric drug discovery
  • Tissue regeneration biotech
  • Ion channel modulators

Where Morphoceuticals is headquartered

Location

Headquarters

HQ city
Medford
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Morphoceuticals business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Electroceutical Therapeutics: Pre-revenue biotech company developing AI-guided electroceuticals for tissue repair and organ regeneration. Revenue generation model not yet established as company is in R&D stage.
  2. Platform Technology Licensing: The company may pursue licensing agreements with large pharmaceutical companies for its bioelectrome platform technology and therapeutic candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Morphoceuticals product offering

Product offering

Core offering

Morphoceuticals is a TechBio company building the first atlas of the bioelectrome—the set of electrical communication networks within the body that coordinate tissue repair and organ regeneration. Using multi-omics analysis, bioelectric profiling, and proprietary AI techniques, the company discovers and develops ion channel and gap junction modulators (electroceuticals) intended to induce limb regeneration, repair tissues, regenerate organs, and treat channelopathies. The platform is delivered alongside wearable bioreactor devices (biodomes) that establish localized controlled environments for electroceutical delivery.

Product overview

Morphoceuticals is a TechBio company offering a platform technology centered on the first-ever atlas of the bioelectrome. The core platform combines multi-omics analysis, bioelectric profiling, and AI to map and manipulate the body's electrical communication networks. The technology is delivered through AI-guided electroceuticals (ion channel and gap junction modulators) and wearable bioreactor devices (biodomes) that enable targeted bioelectric signaling for tissue repair and organ regeneration. The company is pursuing applications in limb regeneration, wound healing, organ repair, and treatment of degenerative diseases and traumatic injuries.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bioelectrome Atlas Platform First-ever atlas of the bioelectrome—a comprehensive map of electrical communication networks within the body that bind multi-cellular collectives together, built using multi-omics, bioelectric profiling, and proprietary AI techniques. Used as a discovery engine for identifying regenerative therapeutic targets.
  • AI-Guided Electroceuticals Proprietary combinations of ion channel and gap junction modulators guided by AI to induce tissue regeneration, improve amputation stump health, promote organ regeneration, and treat channelopathies. Aimed at patients with traumatic injuries, degenerative diseases, and organ failure.
  • Wearable Bioreactor (Biodome) Wearable device (biodome) that establishes a temporary hydrated and controlled environment at a stump or wound site, enabling localized delivery of electroceuticals to trigger regenerative bioelectric signaling. Used in combination with Morphoceuticals' ion channel and gap junction modulators.

Quantifiable outcome

  • Functional limb regeneration achieved in adult African clawed frogs (species that does not naturally regenerate complex limbs)
  • +2 more outcomes

Companies that use Morphoceuticals

Customer profile

Segments1 record

Ideal customer profiles2 records

Morphoceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Morphoceuticals partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • LyGenesisminorStrategic or Co-development Partner · 22 July 2025LyGenesis CEO Michael Hufford serves on Morphoceuticals' Board of Directors, creating a strategic connection between the two regenerative medicine companies.
  • Tufts UniversitycoreStrategic or Co-development Partner · 1 January 2020Morphoceuticals was co-founded by Tufts University researchers Michael Levin and David Kaplan. The company leverages groundbreaking research from Tufts including limb regeneration demonstrated in African clawed frogs. The Allen Discovery Center at Tufts is led by Dr. Levin.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Morphoceuticals competitors and assessment

Company assessment

Broad incumbents

  • electroCore: Public bioelectronic medicine company with FDA-cleared vagus nerve stimulation devices for multiple neurological conditions. Comparable through its electroceutical approach and neuromodulation platform, though applied to non-regenerative indications.
  • Saluda Medical: Commercial-stage neuromodulation/electroceutical company with closed-loop spinal cord stimulation platform. Comparable through its use of electrical signaling to treat disease, though focused on pain management rather than regeneration.
  • eGenesis: Clinical-stage gene editing company developing human-compatible organs for xenotransplantation. Comparable through its novel approach to addressing organ failure and regenerative medicine ambitions, though via a different mechanism (xenotransplantation vs. bioelectric signaling).
  • Lineage Cell Therapeutics: Public clinical-stage cell therapy company developing allogeneic cell transplants for neurodegenerative, oncologic, and regenerative indications. Comparable through its regenerative medicine platform and pursuit of novel tissue-restoration therapies.
  • Organogenesis: Public regenerative medicine company commercializing advanced wound care and surgical biologics products. Comparable through its regenerative medicine focus and commercial-stage presence, though in adjacent tissue repair applications rather than whole-organ regeneration.
  • MiMedx: Public regenerative medicine company marketing placental tissue allografts for wound care and surgical recovery. Comparable through its regenerative medicine positioning and focus on tissue repair, though in established wound healing markets rather than bioelectric approaches.

Direct peers

  • LyGenesis: Clinical-stage cell therapy company developing in vivo organ regeneration using lymph nodes as bioreactors. Most directly comparable to Morphoceuticals through its regenerative medicine ambition, board-level connection (LyGenesis CEO Hufford serves on Morphoceuticals' board), and shared focus on organ regrowth without traditional transplantation.
  • Humacyte: Public regenerative medicine company bioengineering human tissues and vessels for implantation. Comparable through its tissue engineering platform targeting regenerative applications and pursuit of FDA approval pathways for novel regenerative products.
  • SetPoint Medical: Clinical-stage bioelectronic medicine company developing vagus nerve stimulation for inflammatory and autoimmune diseases. Closely comparable to Morphoceuticals through its bioelectric therapeutic modality and proprietary neuro-immune mechanism, though targeting different indications.

Emerging players

  • InVivo Therapeutics: Clinical-stage company developing neural regeneration therapies for spinal cord injury and other CNS conditions. Comparable through its regenerative medicine focus and use of novel biomaterial-based approaches for nerve repair.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Morphoceuticals social profiles

Digital presence

Morphoceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Morphoceuticals leadership team

Management profile

Number of profiles

Profiles13 records

Morphoceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Morphoceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Morphoceuticals

What does Morphoceuticals do?

Morphoceuticals is a TechBio company building the first atlas of the bioelectrome—the set of electrical communication networks within the body that coordinate tissue repair and organ regeneration. Using multi-omics analysis, bioelectric profiling, and proprietary AI techniques, the company discovers and develops ion channel and gap junction modulators (electroceuticals) intended to induce limb regeneration, repair tissues, regenerate organs, and treat channelopathies. The platform is delivered alongside wearable bioreactor devices (biodomes) that establish localized controlled environments for electroceutical delivery.

Is Morphoceuticals a public or private company?

Morphoceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Morphoceuticals founded?

Morphoceuticals was founded in 2020. It employs 1 to 10 people.

Where is Morphoceuticals based?

Morphoceuticals is headquartered in Medford, United States, in the North America region.

How does Morphoceuticals make money?

Two revenue lines are on record. Electroceutical Therapeutics are the primary driver. The others are platform Technology Licensing.

Who are Morphoceuticals's main competitors?

Broad incumbents on record are electroCore, Saluda Medical, eGenesis, Lineage Cell Therapeutics, Organogenesis and MiMedx. Direct peers are LyGenesis, Humacyte and SetPoint Medical. InVivo Therapeutics is listed as an emerging player.

Does Morphoceuticals have an API?

No public API is recorded for Morphoceuticals.

What industry is Morphoceuticals in?

Morphoceuticals's product category is Regenerative Medicine Therapeutics. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Morphoceuticals: Interview With CEO Jim Jenson About The Tissue Regeneration And Disease Treatment CompanyMorphoceuticals CEO Jim Jenson described the company's AI-driven platform targeting the bioelectrome for tissue repair and disease treatment. The company has raised over $15 million in seed funding and is seeking a $10 million bridge. It plans to develop preliminary bioelectric simulations and proof-of-concept in disease models within the next year.SecSEC FORM DMorphoceuticals, Inc. filed a Form D with the Securities and Exchange Commission to announce an exempt securities offering under Rule 506(b) beginning on September 23, 2024. The company is raising up to $5.5 million in equity securities, with $3.5 million already sold to one investor at the time of filing.163Pioneering bioelectric reprogramming, regenerative medicine receives $8 million investment, adult clawed frog limb regenerationMorphoceuticals completed an $8 million funding round led by Prime Movers Lab to advance the use of electrotherapy in regenerative medicine. Founded by researchers from Tufts University, the company aims to trigger limb regeneration in adults, as demonstrated in studies involving African clawed frogs. The funding will help test new electrochemical combinations for limb regeneration and develop tools for mapping live tissue bioelectric profiles.BostonGlobe.comBoston biotech has raised nearly $10 million to study limb regrowthMorphoceuticals, a Boston biotech founded by Tufts professors, raised about $9.7 million to advance limb regrowth research, including $8 million announced Wednesday. The company's technology, based on frog limb regeneration, aims to treat human amputations, with 185,000 performed annually in the US.Venture Capital Access OnlineMorphoceuticals Raises $8 million to Advance Electroceutical Approach to Regenerative MedicineMorphoceuticals Inc. closed an $8 million Seed-2 funding round led by Prime Movers Lab, with initial investor Juvenescence also participating. The capital will be used to advance the company's AI-guided electroceutical therapies for limb regeneration and organ repair, building on prior success in regenerating limbs in adult frogs. This development aims to address the significant number of amputations performed annually in the United States.PR NewswireMorphoceuticals Raises $8 million to Advance Electroceutical Approach to Regenerative MedicineMorphoceuticals Inc. has closed an $8 million Seed-2 funding round led by Prime Movers Lab, with initial investor Juvenescence also participating. The company is leveraging this capital to advance its AI-guided electroceutical technology for regenerative medicine, aiming to develop therapies for limb regeneration and organ repair based on successful trials in adult frogs. This investment supports the transition of their bioelectric signaling treatments from preclinical studies toward clinical testing.SecSEC FORM DMorphoceuticals, Inc. filed a Form D with the SEC to report an exempt offering of equity securities under Rule 506(b). The company raised a total of $9,820,000 from three investors, with proceeds intended for general corporate purposes and executive compensation.PR NewswireMorphoceuticals Inc. Hails Successful Limb Regeneration in Adult Frogs using a Novel Drug CombinationMorphoceuticals Inc. announced the successful regeneration of functional limbs in adult African clawed frogs using a novel multidrug treatment delivered via a wearable bioreactor. This breakthrough, published in Science Advances by co-founders from Tufts University, demonstrates the ability to kickstart endogenous regenerative pathways in vertebrates that do not typically regenerate complex limbs in adulthood. The company is now focused on developing these bioelectric approaches for potential therapeutic applications in humans.